2WM Stock Overview
Through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cansortium Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$0.17 |
| 52 Week Low | US$0.11 |
| Beta | 3.13 |
| 11 Month Change | -28.89% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2WM | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.4% | -3.7% | -0.5% |
| 1Y | n/a | -20.5% | 1.6% |
Return vs Industry: Insufficient data to determine how 2WM performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2WM performed against the German Market.
Price Volatility
| 2WM volatility | |
|---|---|
| 2WM Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2WM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2WM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Robert Beasley | getfluent.com |
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in Florida, Pennsylvania, and Texas. The company’s medical cannabis products are offered in oral drops, capsules, topicals, syringes, dried flower, pre-rolls, cartridges, concentrates, and edibles under the Fluent brand name. It also sells various third-party branded medical cannabis products.
Cansortium Inc. Fundamentals Summary
| 2WM fundamental statistics | |
|---|---|
| Market cap | €36.24m |
| Earnings (TTM) | -€18.17m |
| Revenue (TTM) | €93.49m |
0.4x
P/S Ratio-1.9x
P/E RatioIs 2WM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2WM income statement (TTM) | |
|---|---|
| Revenue | US$100.46m |
| Cost of Revenue | US$45.51m |
| Gross Profit | US$54.96m |
| Other Expenses | US$74.49m |
| Earnings | -US$19.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.065 |
| Gross Margin | 54.70% |
| Net Profit Margin | -19.44% |
| Debt/Equity Ratio | 1,405.9% |
How did 2WM perform over the long term?
See historical performance and comparison